The offered technology uses innovative nanovesicles as delivery vehicles. Unlike today's technologies that encapsulate the payload in the lumen of the nanovesicle, the technology covalently embeds the drug in the outer lipid shell. Once delivered into the membrane of the target cell, the agent is slowly cleaved and delivered to its site of action. The covalent release leads to a reduced peak and longer residence of the drug in the target environment. The value of the technology has been exemplified using Camptothecin, a widely used cancer drug. Camptothecin suffers from unfavorable distribution in the body and severe toxic side effects. Delivering Camptothecin through the novel technology has proven to be more effective and better tolerated than current standard of care in various mouse cancer models.